NewAmsterdam Historical Financial Ratios

NAMS Stock   20.84  0.21  1.00%   
NewAmsterdam Pharma is lately reporting on over 85 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 6.3 will help investors to properly organize and evaluate NewAmsterdam Pharma financial condition quickly.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

About NewAmsterdam Financial Ratios Analysis

NewAmsterdam PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate NewAmsterdam Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on NewAmsterdam financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across NewAmsterdam Pharma history.

NewAmsterdam Pharma Financial Ratios Chart

At this time, NewAmsterdam Pharma's Ebt Per Ebit is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 3.02 in 2024, despite the fact that Free Cash Flow Per Share is likely to grow to (1.63).
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing NewAmsterdam Pharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on NewAmsterdam Pharma sales, a figure that is much harder to manipulate than other NewAmsterdam Pharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.
Most ratios from NewAmsterdam Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into NewAmsterdam Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.At this time, NewAmsterdam Pharma's Ebt Per Ebit is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 3.02 in 2024, despite the fact that Free Cash Flow Per Share is likely to grow to (1.63).
 2023 2024 (projected)
Graham Number13.0410.2
Receivables Turnover41.737.06

NewAmsterdam Pharma fundamentals Correlations

0.66-0.950.16-0.76-0.79-0.780.661.0-0.790.08-0.780.761.00.170.360.950.490.36-0.15-0.690.780.680.120.78-0.72
0.66-0.620.65-0.62-0.61-0.821.00.66-0.610.59-0.960.820.660.650.860.630.90.86-0.66-0.990.781.00.580.78-0.95
-0.95-0.62-0.170.730.740.73-0.62-0.950.74-0.070.74-0.72-0.95-0.18-0.34-0.8-0.46-0.340.170.64-0.74-0.64-0.1-0.740.68
0.160.65-0.170.190.19-0.730.650.160.190.99-0.40.760.161.00.940.120.910.94-1.0-0.550.030.580.990.02-0.37
-0.76-0.620.730.191.00.35-0.62-0.761.00.270.82-0.33-0.760.19-0.13-0.72-0.22-0.13-0.180.7-0.97-0.680.27-0.970.83
-0.79-0.610.740.191.00.38-0.61-0.791.00.270.82-0.36-0.790.18-0.13-0.77-0.23-0.13-0.180.7-0.97-0.670.26-0.970.82
-0.78-0.820.73-0.730.350.38-0.82-0.780.38-0.690.74-1.0-0.78-0.74-0.82-0.74-0.89-0.820.730.78-0.51-0.8-0.72-0.50.67
0.661.0-0.620.65-0.62-0.61-0.820.66-0.610.59-0.960.820.660.650.860.630.90.86-0.66-0.990.781.00.580.78-0.95
1.00.66-0.950.16-0.76-0.79-0.780.66-0.790.08-0.780.761.00.170.360.950.490.36-0.15-0.690.780.680.120.78-0.72
-0.79-0.610.740.191.01.00.38-0.61-0.790.270.82-0.36-0.790.18-0.13-0.77-0.23-0.13-0.180.7-0.97-0.670.26-0.970.82
0.080.59-0.070.990.270.27-0.690.590.080.27-0.330.710.080.990.920.080.880.92-0.99-0.49-0.050.521.0-0.05-0.29
-0.78-0.960.74-0.40.820.820.74-0.96-0.780.82-0.33-0.73-0.78-0.41-0.68-0.74-0.74-0.670.410.98-0.93-0.97-0.32-0.930.99
0.760.82-0.720.76-0.33-0.36-1.00.820.76-0.360.71-0.730.760.760.840.720.90.84-0.75-0.770.490.790.740.48-0.66
1.00.66-0.950.16-0.76-0.79-0.780.661.0-0.790.08-0.780.760.170.360.950.490.36-0.15-0.690.780.680.120.78-0.72
0.170.65-0.181.00.190.18-0.740.650.170.180.99-0.410.760.170.940.140.910.94-1.0-0.560.030.590.990.03-0.37
0.360.86-0.340.94-0.13-0.13-0.820.860.36-0.130.92-0.680.840.360.940.340.991.0-0.95-0.80.350.820.910.35-0.65
0.950.63-0.80.12-0.72-0.77-0.740.630.95-0.770.08-0.740.720.950.140.340.470.34-0.12-0.660.750.660.130.75-0.68
0.490.9-0.460.91-0.22-0.23-0.890.90.49-0.230.88-0.740.90.490.910.990.470.99-0.91-0.840.430.860.880.43-0.7
0.360.86-0.340.94-0.13-0.13-0.820.860.36-0.130.92-0.670.840.360.941.00.340.99-0.95-0.80.350.820.910.35-0.65
-0.15-0.660.17-1.0-0.18-0.180.73-0.66-0.15-0.18-0.990.41-0.75-0.15-1.0-0.95-0.12-0.91-0.950.56-0.04-0.59-0.98-0.040.38
-0.69-0.990.64-0.550.70.70.78-0.99-0.690.7-0.490.98-0.77-0.69-0.56-0.8-0.66-0.84-0.80.56-0.84-1.0-0.48-0.840.98
0.780.78-0.740.03-0.97-0.97-0.510.780.78-0.97-0.05-0.930.490.780.030.350.750.430.35-0.04-0.840.83-0.061.0-0.93
0.681.0-0.640.58-0.68-0.67-0.81.00.68-0.670.52-0.970.790.680.590.820.660.860.82-0.59-1.00.830.510.82-0.97
0.120.58-0.10.990.270.26-0.720.580.120.261.0-0.320.740.120.990.910.130.880.91-0.98-0.48-0.060.51-0.06-0.28
0.780.78-0.740.02-0.97-0.97-0.50.780.78-0.97-0.05-0.930.480.780.030.350.750.430.35-0.04-0.841.00.82-0.06-0.93
-0.72-0.950.68-0.370.830.820.67-0.95-0.720.82-0.290.99-0.66-0.72-0.37-0.65-0.68-0.7-0.650.380.98-0.93-0.97-0.28-0.93
Click cells to compare fundamentals

NewAmsterdam Pharma Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.